Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ukraine confirms defence and energy ministers at second attempt - 2Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- 3Remain Fit and Sound with These Exercise Fundamentals
- 4Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- 5Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
- Embrace the Outside: Exercises and Entertainment
- Finding the Universe of Computer generated Reality: Individual Encounters
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- Self-sacrificing ants highlight the unity of their colony, say researchers
- Scientists solve the mystery of the prehistoric 'Burtele Foot'
- Vote In favor of Your Favored Web-based Venture Stage
- Nature's Treats: 10 Organic products That Lift Prosperity
